Compare Stocks: CPRX, NBIX, CORT, and ELAN

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CORT Corcept Therapeutics	$113.34 +0.3%	$110.12	$28.66 ▼ $126.38	$12.26B	0.45	1.54 million shs	151,024 shs
CPRX Catalyst Pharmaceuticals	$31.49	$31.46	$19.05 ▼ $32.56	$3.86B	0.74	2.62 million shs	N/A
ELAN Elanco Animal Health	$21.82 -3.3%	$24.18	$18.48 ▼ $27.98	$10.93B	1.68	5.63 million shs	1.35 million shs
NBIX Neurocrine Biosciences	$138.65 -0.6%	$159.96	$122.14 ▼ $186.12	$14.10B	0.38	1.20 million shs	278,474 shs

7 Stocks That Could Lead the Next Market Boom

Tesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CORT Corcept Therapeutics	-3.88%	+1.01%	-8.36%	+33.26%	+35.55%
CPRX Catalyst Pharmaceuticals	0.00%	0.00%	0.00%	+0.22%	+59.20%
ELAN Elanco Animal Health	-1.33%	-1.12%	-7.35%	-7.16%	+21.84%
NBIX Neurocrine Biosciences	-1.94%	-6.70%	-8.85%	-15.04%	-4.72%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CORT Corcept Therapeutics	$113.34 +0.3%	$110.12	$28.66 ▼ $126.38	$12.26B	0.45	1.54 million shs	151,024 shs
CPRX Catalyst Pharmaceuticals	$31.49	$31.46	$19.05 ▼ $32.56	$3.86B	0.74	2.62 million shs	N/A
ELAN Elanco Animal Health	$21.82 -3.3%	$24.18	$18.48 ▼ $27.98	$10.93B	1.68	5.63 million shs	1.35 million shs
NBIX Neurocrine Biosciences	$138.65 -0.6%	$159.96	$122.14 ▼ $186.12	$14.10B	0.38	1.20 million shs	278,474 shs

7 Stocks That Could Lead the Next Market Boom

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CORT Corcept Therapeutics	-3.88%	+1.01%	-8.36%	+33.26%	+35.55%
CPRX Catalyst Pharmaceuticals	0.00%	0.00%	0.00%	+0.22%	+59.20%
ELAN Elanco Animal Health	-1.33%	-1.12%	-7.35%	-7.16%	+21.84%
NBIX Neurocrine Biosciences	-1.94%	-6.70%	-8.85%	-15.04%	-4.72%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CORT Corcept Therapeutics	2.50	Moderate Buy	$138.17	21.91% Upside
CPRX Catalyst Pharmaceuticals	2.56	Moderate Buy	$32.00	1.62% Upside
ELAN Elanco Animal Health	2.75	Moderate Buy	$29.70	36.14% Upside
NBIX Neurocrine Biosciences	2.88	Moderate Buy	$201.09	45.04% Upside

Current Analyst Ratings Breakdown

Latest CPRX, NBIX, CORT, and ELAN Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/18/2026	CORT Corcept Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$165.00
9/16/2026	NBIX Neurocrine Biosciences	Mizuho Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold
9/11/2026	NBIX Neurocrine Biosciences	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Equal Weight	$182.00 ➝ $183.00
9/8/2026	CORT Corcept Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Hold (C) ➝ Hold (C-)
9/8/2026	NBIX Neurocrine Biosciences	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Buy (B) ➝ Buy (B-)
9/8/2026	NBIX Neurocrine Biosciences	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Outperform	$198.00
9/4/2026	ELAN Elanco Animal Health	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (D) ➝ Sell (D+)
9/3/2026	NBIX Neurocrine Biosciences	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$249.00 ➝ $253.00
8/25/2026	NBIX Neurocrine Biosciences	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Buy (B-) ➝ Buy (B)
8/20/2026	CORT Corcept Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold (C-) ➝ Hold (C)
8/20/2026	ELAN Elanco Animal Health	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D+) ➝ Sell (D)

(Data available from 9/24/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CORT Corcept Therapeutics	$761.41M	16.09	$0.87 per share	130.16	$6.16 per share	18.40
CPRX Catalyst Pharmaceuticals	$596.96M	6.46	$2.92 per share	10.77	$7.76 per share	4.06
ELAN Elanco Animal Health	$5.02B	2.17	$2.21 per share	9.88	$13.18 per share	1.66
NBIX Neurocrine Biosciences	$2.86B	4.93	$4.89 per share	28.38	$32.63 per share	4.25

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CORT Corcept Therapeutics	$99.65M	$0.42	270.02	32.57	N/A	6.52%	8.26%	6.45%	11/4/2026 (Estimated)
CPRX Catalyst Pharmaceuticals	$214.33M	$1.74	18.10	10.22	0.96	37.08%	35.76%	31.31%	N/A
ELAN Elanco Animal Health	-$232M	-$0.41	N/A	16.91	1.63	-3.96%	8.13%	3.99%	11/6/2026 (Estimated)
NBIX Neurocrine Biosciences	$478.60M	$6.82	20.34	14.66	0.66	20.91%	22.43%	15.64%	10/27/2026 (Estimated)

Latest CPRX, NBIX, CORT, and ELAN Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/5/2026	Q2 2026	ELAN Elanco Animal Health	$0.2692	$0.34	+$0.0708	$0.11	$1.31 billion	$1.37 billion
7/31/2026	Q2 2026	NBIX Neurocrine Biosciences	$1.65	$2.85	+$1.20	$1.39	$891.16 million	$959.00 million
7/29/2026	Q2 2026	CORT Corcept Therapeutics	$0.0243	$0.36	+$0.3357	$0.36	$221.15 million	$256.15 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
CORT Corcept Therapeutics	N/A	N/A	N/A	N/A	N/A
CPRX Catalyst Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
ELAN Elanco Animal Health	N/A	N/A	N/A	N/A	N/A
NBIX Neurocrine Biosciences	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CORT Corcept Therapeutics	N/A	2.86	2.77
CPRX Catalyst Pharmaceuticals	N/A	7.10	6.84
ELAN Elanco Animal Health	0.58	2.05	1.10
NBIX Neurocrine Biosciences	N/A	1.87	1.75

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CORT Corcept Therapeutics	93.61%
CPRX Catalyst Pharmaceuticals	79.22%
ELAN Elanco Animal Health	97.48%
NBIX Neurocrine Biosciences	92.59%

Insider Ownership

Company	Insider Ownership
CORT Corcept Therapeutics	20.70%
CPRX Catalyst Pharmaceuticals	10.40%
ELAN Elanco Animal Health	1.14%
NBIX Neurocrine Biosciences	4.60%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CORT Corcept Therapeutics	730	108.10 million	85.72 million	Optionable
CPRX Catalyst Pharmaceuticals	80	122.42 million	109.69 million	Optionable
ELAN Elanco Animal Health	9,400	499.62 million	493.93 million	Optionable
NBIX Neurocrine Biosciences	2,000	101.65 million	96.97 million	Optionable

CPRX, NBIX, CORT, and ELAN Headlines

Recent News About These Companies

Andra AP fonden Lowers Holdings in Neurocrine Biosciences, Inc. $NBIX

September 23 at 3:20 AM | marketbeat.com

Neurocrine Maps AI, China and Pipeline Strategy as INGREZZA Faces 2029 Price Hit

September 22 at 12:01 AM | marketbeat.com

Nykredit A S Makes New $5.19 Million Investment in Neurocrine Biosciences, Inc. $NBIX

September 22 at 3:20 AM | marketbeat.com

RBC Cuts Price Target on Neurocrine Biosciences to $187 From $198, Keeps Outperform Rating

September 21 at 8:16 PM | finance.yahoo.com

Neurocrine Biosciences stock draws support from strong Q2 figures

September 19, 2026 | ad-hoc-news.deA

Bank of America Corp DE Buys New Stake in Neurocrine Biosciences, Inc. $NBIX

September 19, 2026 | marketbeat.com

Neurocrine Biosciences Director Kevin Charles Increases Stake to 525,636 Shares Following Share Award

September 18, 2026 | kalkinemedia.comK

CCB Int'l Starts Neurocrine Bio. (NBIX) at Outperform

September 18, 2026 | streetinsider.com

Mizuho Upgrades Neurocrine Biosciences (NASDAQ:NBIX) to Hold

September 18, 2026 | marketbeat.com

Neurocrine’s (NBIX) Data Deluge Reshapes A Familiar Growth Story

September 18, 2026 | insidermonkey.com

Matt Abernethy Sells 2,311 Shares of Neurocrine Biosciences (NASDAQ:NBIX) Stock

September 17, 2026 | americanbankingnews.com

Corient Private Wealth LP Buys 9,645 Shares of Neurocrine Biosciences, Inc. $NBIX

September 17, 2026 | marketbeat.com

David Boyer Sells 826 Shares of Neurocrine Biosciences (NASDAQ:NBIX) Stock

September 16, 2026 | insidertrades.com

Neurocrine Biosciences, Inc. (NBIX) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

September 15, 2026 | seekingalpha.com

Insider Selling: Neurocrine Biosciences (NASDAQ:NBIX) Insider Sells 826 Shares of Stock

September 15, 2026 | marketbeat.com

Insider Selling: Neurocrine Biosciences (NASDAQ:NBIX) CFO Sells $363,289.20 in Stock

September 15, 2026 | marketbeat.com

National Pension Service Sells 15,042 Shares of Neurocrine Biosciences, Inc. $NBIX

September 14, 2026 | marketbeat.com

Engineers Gate Manager LP Increases Holdings in Neurocrine Biosciences, Inc. $NBIX

September 14, 2026 | marketbeat.com

Morgan Stanley Raises Neurocrine Biosciences (NASDAQ:NBIX) Price Target to $183.00

September 13, 2026 | americanbankingnews.com

Tidal Investments LLC Raises Stake in Neurocrine Biosciences, Inc. $NBIX

September 12, 2026 | marketbeat.com

RFG Advisory LLC Invests $1.38 Million in Neurocrine Biosciences, Inc. $NBIX

September 12, 2026 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

CPRX, NBIX, CORT, and ELAN Company Descriptions

Corcept Therapeutics NASDAQ:CORT

$113.34 +0.40 (+0.35%)

As of 12:04 PM Eastern

Corcept Therapeutics Incorporated engages in discovery and development of drugs for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. It offers Korlym tablets medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous cushing's syndrome; and who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery. The company is also developing relacorilant, which is in phase III clinical trial for the treatment of cushing's syndrome; treatment for adrenal cancer and cortisol excess which is in phase 1b clinical trial; treatment for prostate cancer which is in phase II clinical trial; and nab-paclitaxel in combination with relacorilant, which is in phase III clinical trial to treat platinum-resistant ovarian tumors. In addition, it develops dazucorilant, which is in phase II clinical trial for the treatment of amyotrophic lateral sclerosis; miricorilant, which is in phase IIb trial for the treatment of nonalcoholic steatohepatitis; and treatment for antipsychotic induced weight gain that is in phase I trial. The company was incorporated in 1998 and is headquartered in Menlo Park, California.

Catalyst Pharmaceuticals NASDAQ:CPRX

Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients. The company develops Firdapse for the treatment of MuSK antibody positive myasthenia gravis and spinal muscular atrophy type. It has license agreements with BioMarin Pharmaceutical Inc.; and collaboration and license agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets. The company was founded in 2002 and is based in Coral Gables, Florida.

Elanco Animal Health NYSE:ELAN

$21.82 -0.76 (-3.35%)

As of 12:04 PM Eastern

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands. The company sells its products to third-party distributors; veterinarians; and farm animal producers, including beef and dairy farmers, as well as pork, poultry, and aquaculture operations. Elanco Animal Health Incorporated was founded in 1954 and is headquartered in Greenfield, Indiana.

Neurocrine Biosciences NASDAQ:NBIX

$138.65 -0.84 (-0.60%)

As of 12:04 PM Eastern

Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids. Its product candidates in clinical development include valbenazine to treat dyskinetic cerebral palsy in pediatrics and adults; NBI-921352 to treat developmental and epileptic encephalopathy syndrome in pediatrics and adults; NBI-827104 to treat epileptic encephalopathy with continuous spike-and-wave during sleep; NBI-1076986 to treat movement disorders; crinecerfront to treat congenital adrenal hyperplasia in adults and children; EFMODY to treat congenital adrenal hyperplasia and adrenal insufficiency in adults; valbenazine for the adjunctive treatment of schizophrenia; NBI-1065845 for the treatment of inadequate response to treatment in major depressive disorder; luvadaxistat to treat cognitive impairment related to schizophrenia; NBI-1117568 for the treatment of schizophrenia; NBI-1070770 to treat major depressive disorder; NBI-1117570 for the treatment of symptoms of psychosis and cognition in neurological and neuropsychiatric conditions; and NBI-1117569, NBI-1117567, and NBI-1065890 to treat CNS indications. The company also has license and collaboration agreements with Heptares Therapeutics Limited; Takeda Pharmaceutical Company Limited; Idorsia Pharmaceuticals Ltd; Xenon Pharmaceuticals Inc.; Voyager Therapeutics, Inc.; BIAL Portela & Ca, S.A.; Mitsubishi Tanabe Pharma Corporation; and AbbVie Inc. The company was incorporated in 1992 and is headquartered in San Diego, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest CPRX, NBIX, CORT, and ELAN Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest CPRX, NBIX, CORT, and ELAN Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

CPRX, NBIX, CORT, and ELAN Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

CPRX, NBIX, CORT, and ELAN Company Descriptions

Corcept Therapeutics NASDAQ:CORT

Catalyst Pharmaceuticals NASDAQ:CPRX

Elanco Animal Health NYSE:ELAN

Neurocrine Biosciences NASDAQ:NBIX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest CPRX, NBIX, CORT, and ELAN Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest CPRX, NBIX, CORT, and ELAN Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

CPRX, NBIX, CORT, and ELAN Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

CPRX, NBIX, CORT, and ELAN Company Descriptions

Corcept Therapeutics NASDAQ:CORT

Catalyst Pharmaceuticals NASDAQ:CPRX

Elanco Animal Health NYSE:ELAN

Neurocrine Biosciences NASDAQ:NBIX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools